CJ to introduce FSAD treatment Femprox

Published: 2003-12-08 06:56:00

Updated: 2003-12-08 06:56:00

CJ announced it entered into an exclusive distribution agreement with the U.S.-based NexMed Inc. on November 21 for the introduction of Femprox, which is effective in treating female sexual arousal disorder (FSAD).

Femprox cream incorporates alprostadil (prostaglandin E1) with NexMed's patente...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK